ILMN at a glance
Illumina Inc (ILMN, SEC CIK 1110803) filed its latest 10-K annual report on February 12, 2026, a 10-Q quarterly report on July 31, 2026, an 8-K current report on August 17, 2026 and Form 4 insider filings as recently as October 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 28, 2025 (FY2025), Illumina Inc (ILMN) reported revenue of $4.3 billion (down 0.7% from FY2024) and net income of $850.0 million. Diluted EPS was $5.45.
- As of June 30, 2026, 45 institutional investment managers tracked by SignalX reported holding Illumina Inc (ILMN) shares worth $11.1 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Meister Keith A. on September 4, 2026 of 11,351 shares at $219.18 per share.
- In the last 90 days, ILMN insiders reported 0 open-market purchases ($0) and 69 open-market sales ($436.5M) on Form 4, a net sale of $436.5M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $4.3B
- −0.7% vs prior year
- Insiders · 90 days
- 0 buys · 69 sells
- Net −$436.5M
- 13F holders
- 45 funds
- $11.1B · +5 vs prior quarter
- Latest 10-Q
- Jul 31, 2026
- Quarterly report
SignalX for ILMN
Don't miss the next ILMN filing
- Alerts as it files. A push when ILMN files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ILMN, by share count.
- Ask anything. An AI agent that reads every ILMN filing and answers with sources.
ILMN alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Ullem Scott B. | A | Sep 30, 2026 | 113 | $219.80 |
| Meister Keith A. | A | Sep 30, 2026 | 107 | $219.80 |
| Coletti Julie Ann | A | Sep 8, 2026 | 5,307 | - |
| Coletti Julie Ann | A | Sep 8, 2026 | 14,214 | - |
| Coletti Julie Ann | A | Sep 8, 2026 | 5,307 | - |
| Coletti Julie Ann | A | Sep 8, 2026 | 4,549 | - |
| Barnard Steven | F | Sep 5, 2026 | 408 | $211.06 |
| Meister Keith A. | Sell | Sep 4, 2026 | 11,351 | $219.18 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $4.4B | $4.3B |
| Gross Profit | - | $2.9B | $2.9B |
| Operating Income | - | -$833.0M | $807.0M |
| Net Income | - | -$1.2B | $850.0M |
| Gross Margin | - | 65.4% | 66.1% |
| Op. Margin | - | -19.1% | 18.6% |
| Net Margin | - | -28.0% | 19.6% |
| Balance Sheet | |||
| Total Assets | $10.1B | $6.3B | $6.6B |
| Equity | $5.7B | $2.4B | $2.7B |
| ROE | - | -51.5% | 31.2% |
| Per Share | |||
| EPS | - | $-7.69 | $5.45 |
| Cash Flow | |||
| Operating CF | - | $837.0M | $1.1B |
| CapEx | - | $128.0M | $148.0M |
Source: XBRL data in Illumina Inc (ILMN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate ILMN share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 45 | $11.15B |
| Q1 2026 | 40 | $7.59B |
| Q4 2025 | 38 | $8.34B |
| Q3 2025 | 39 | $5.86B |
| Q2 2025 | 37 | $5.91B |
| Q1 2025 | 32 | $3.17B |
| Q4 2024 | 30 | $4.68B |
| Q3 2024 | 25 | $2.70B |
- FMR LLC (Fidelity)+2.98M (+192%)
- Goldman Sachs Group+237.5K (+31%)
- BNY Mellon+171.2K (+11%)
- BlackRock+167.8K (+1%)
- JPMorgan Chase & Co+149.9K (+15%)
- Invesco Ltd−663.4K (-25%)
- AQR Capital Management−436.6K (-11%)
- Vanguard Portfolio Management LLC−196.5K (-3%)
- Morgan Stanley−188.9K (-10%)
- Northern Trust−149.1K (-9%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 286 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
Related Health Care companies
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- A · Agilent TechnologiesLaboratory Analytical Instruments
- ALMR · Alamar Biosciences IncLaboratory Analytical Instruments
- AVTR · Avantor IncLaboratory Analytical Instruments
- BIO · Bio-rad Laboratories IncLaboratory Analytical Instruments
- BRKR · Bruker CorpLaboratory Analytical Instruments
- CTKB · Cytek Biosciences, Inc.Laboratory Analytical Instruments
- EYPT · EyePoint, Inc.Laboratory Analytical Instruments
ILMN SEC filings: frequently asked questions
Are ILMN insiders buying or selling?
In the last 90 days, Illumina Inc (ILMN) officers, directors and 10% owners reported no open-market purchases and 69 open-market sales worth $436.5 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold ILMN stock?
As of June 30, 2026, the largest Illumina Inc (ILMN) holders among the 13F filers tracked by SignalX were BlackRock ($3.4 billion), Vanguard Portfolio Management LLC ($1.2 billion), Vanguard Capital Management LLC ($1.2 billion), State Street Corp ($1.1 billion), FMR LLC (Fidelity) ($795.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ILMN's revenue in fiscal year 2025?
For the fiscal year ended December 28, 2025 (FY2025), Illumina Inc (ILMN) reported revenue of $4.3 billion (down 0.7% from FY2024) and net income of $850.0 million. Diluted EPS was $5.45. The figures come from the XBRL data in the 10-K.
What are the latest ILMN SEC filings?
Illumina Inc (ILMN) filed its latest 10-K annual report on February 12, 2026, a 10-Q quarterly report on July 31, 2026, an 8-K current report on August 17, 2026 and a Form 4 insider filing on October 2, 2026.
What is ILMN's SEC CIK number?
Illumina Inc (ILMN)'s SEC Central Index Key (CIK) is 1110803. EDGAR lists every ILMN filing under that number.
Ask anything about ILMN
The research agent reads ILMN's filings, financials, insider trades and 13F holders, then answers with sources.